{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:43:59Z","timestamp":1787777039679,"version":"build-2784847793"},"reference-count":23,"publisher":"e-Century Publishing Corporation","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Transl Res"],"DOI":"10.62347\/mjoa5699","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T04:18:36Z","timestamp":1732853916000},"page":"6955-6963","source":"Crossref","is-referenced-by-count":20,"title":["Predictive and prognostic value of combined detection of sTim-3, PG and PD-L1 in immune checkpoint inhibitor therapy for advanced gastric cancer"],"prefix":"10.62347","volume":"16","author":[{"given":"Hanyong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"48694","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","unstructured":"Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, Vogel A and Smyth EC; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 2022; 33: 1005-1020.","journal-title":"Ann Oncol"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.giec.2021.03.004","article-title":"Endoscopic screening and surveillance for gastric cancer","volume":"31","author":"Kim","year":"2021","unstructured":"Kim B and Cho SJ. Endoscopic screening and surveillance for gastric cancer. Gastrointest Endosc Clin N Am 2021; 31: 489-501.","journal-title":"Gastrointest Endosc Clin N Am"},{"key":"ref2","unstructured":"Zhang Q, Zhou XZ, Cheng S, Meng T, Gao ZJ, Zhang DZ and Zhu SH. Clinical study of peripheral blood inflammatory indexes in the therapeutic effect and prognostic value of immune checkpoint inhibitors in advanced gastric cancer. Chin Gene Med 2024; 22; 198-201."},{"key":"ref3","unstructured":"Xiong B, He XZ, Ye XL, Wang DY and Zhang JL. The value of serum soluble Tim-3 in predicting the efficacy and prognosis of arterial chemoembolization therapy for hepatocellular carcinoma. Chin Clin Oncol 2022; 27: 527-532."},{"key":"ref4","unstructured":"Zhou S, Wang K, He JX, Yang XJ and Yang P. Analysis of the correlation between serum PG, LGR4 and the prognosis of laparoscopic D2 radical surgery in patients with gastric cancer. Prog Mod Biomed 2022; 22: 3051-3054."},{"key":"ref5","unstructured":"Zuo XL, Chen ZQ, Dong RY, Wang ZX and Cai J. The value of combined detection of LDHA and PD-L1 in the prediction of efficacy and prognostic assessment of PD-1 inhibitors in advanced gastric cancer. Chin Oncol 2023; 33: 460-468."},{"key":"ref6","unstructured":"Lu YY, Lu LG and Qian NY. Treatment guidelines for esophageal and stomach cancer. Chin J Gastroenter 2012; 17: 173-175."},{"key":"ref7","unstructured":"Ma LJ, Wang Y and Li DM. Analysis of the correlation and diagnostic value of serum CEA, CYFRA21-1, ALP, ALB and KPS score in lung cancer patients. Labora Med Clin 2022; 19: 454-458."},{"key":"ref8","unstructured":"Yang XN and Wu YL. Criteria for evaluating the efficacy of treatment for solid tumors - RECIST. J Evid Based Med 2004; 4: 85-90."},{"key":"ref9","unstructured":"Yang L, Qin LQ, Geng Q, Li DQ, Qi CJ and Jiang H. Predictive value of soluble immune checkpoints on the efficacy and prognosis of immunotherapy in gastric cancer patients. Chin J Diges Med Image 2023; 13: 305-311."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3322\/caac.21657","article-title":"Current treatment and recent progress in gastric cancer [J]","volume":"71","author":"Joshi","year":"2021","unstructured":"Joshi SS and Badgwell BD. Current treatment and recent progress in gastric cancer [J]. CA Cancer J Clin 2021; 71: 264-279.","journal-title":"CA Cancer J Clin"},{"key":"ref11","unstructured":"Wu X and Tan YQ. Progress of immune checkpoint inhibitors in progressive gastric cancer. Oncol Prog 2023; 21: 1629-1631."},{"key":"ref12","unstructured":"Guo Y, Wei XJ and Gao Q. Regulatory mechanism of Tim-3 aberrant expression in T cells on gastric cancer progression. Chin J Geront 2021; 41: 4834-4837."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s10555-020-09925-3","article-title":"Gastric cancer: a comprehensive review of current and future treatment strategies","volume":"39","author":"Sexton","year":"2020","unstructured":"Sexton RE, Al Hallak MN, Diab M and Azmi AS. Gastric cancer: a comprehensive review of current and future treatment strategies. Cancer Metastasis Rev 2020; 39: 1179-1203.","journal-title":"Cancer Metastasis Rev"},{"key":"ref14","unstructured":"Wang ZY and Gao F. Advances in Tim-3\/Galectin-9 signaling pathway in digestive tract malignancies. Mod Diges Intervent 2022; 27: 118-122."},{"key":"ref15","unstructured":"Zhang XX, Li S, Wu C and Hou XF. Clinical analysis of immunotherapy for advanced gastric esophageal gastric junction adenocarcinoma [J]. Chinese Journal of Oncology 2021; 48: 1208-1214."},{"key":"ref16","unstructured":"Su JQ, Yan HD, Zhou LX, Wang ML, Lin PY, Huang ZS and Li GB. Relationship between changes in serum PG I\/PG II, TK1, CEA levels and prognosis in patients with gastric cancer. Hebei Pharmaceutical 2023; 45: 3239-3244."},{"key":"ref17","unstructured":"Fan JY, Yao Y, Feng L and Huang LL. The value of plasma miR-27b-3p, PG combined with G-17 in early gastric cancer screening. Lab Immun Clin Med 2021; 28: 1556-1559."},{"key":"ref18","unstructured":"Yu JJ, Zhang LK and Yu PP. Correlation of serum c-Myc and PD-L1 levels with clinicopathologic features and prognosis in gastric cancer patients. Guangdong Med J 2024; 45: 220-224."},{"key":"ref19","unstructured":"Xu Y, Tang Y and Li DY. Diagnostic and prognostic value of peripheral blood CTC, PD-L1 and S100A6BP levels in gastric cancer patients. J Mole Diag Thera 2024; 16: 273-277."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"7759","DOI":"10.2147\/CMAR.S328312","article-title":"Clinical value of combined detection of serum stim-3 and pepsinogen for gastric cancer diagnosis","volume":"13","author":"Chen","year":"2021","unstructured":"Chen L, Hong J, Hu R, Yu X, Chen X, Zheng S, Qin Y, Zhou X, Wang Y, Zheng L, Fang H, Liu P and Huang B. Clinical value of combined detection of serum stim-3 and pepsinogen for gastric cancer diagnosis. Cancer Manag Res 2021; 13: 7759-7769.","journal-title":"Cancer Manag Res"},{"key":"ref21","unstructured":"Zheng Y and Chen J. The value of serum IL-6 and pepsinogen I\/II ratio in the prognostic assessment of elderly patients with gastric cancer. Geriatr Heal Care 2022; 28: 120-124."},{"key":"ref22","unstructured":"Zhang X and Fang N. Relationship between serum sTim-3 and YKL-40 levels and recurrence after endoscopic submucosal dissection for early gastric cancer. J Trop Med 2024; 24: 97-101."}],"container-title":["American Journal of Translational Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajtr\/16\/11\/ajtr0159636.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:57:14Z","timestamp":1766023034000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajtr\/16\/11\/ajtr0159636.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":23,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.62347\/mjoa5699","relation":{},"ISSN":["1943-8141"],"issn-type":[{"value":"1943-8141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]}}}